Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer

Oncogenic microRNAs (oncomiRs) accumulate in serum due to their increased stability and thus serve as biomarkers in breast cancer (BC) pathogenesis. Four oncogenic microRNAs (miR-155, miR-19a, miR-181b, and miR-24) and one tumor suppressor microRNA (let-7a) were shown to differentiate between high-...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2017-10, Vol.18 (10), p.2116
Main Authors: Bašová, Petra, Pešta, Michal, Sochor, Marek, Stopka, Tomáš
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Breast cancer
Breast Neoplasms - genetics
Cohort Studies
Data processing
Female
Humans
Ki-67
Ki-67 Antigen - metabolism
Longitudinal Studies
microRNA
MicroRNAs
MicroRNAs - blood
MicroRNAs - genetics
Middle Aged
miR-155
miR-24
miRNA
Multivariate Analysis
Neoplasm Recurrence, Local - diagnosis
Neoplasm Recurrence, Local - genetics
Patients
Polymerase chain reaction
relapse
Serum levels
Surgical instruments
Time Factors
Tumor suppressor genes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncogenic microRNAs (oncomiRs) accumulate in serum due to their increased stability and thus serve as biomarkers in breast cancer (BC) pathogenesis. Four oncogenic microRNAs (miR-155, miR-19a, miR-181b, and miR-24) and one tumor suppressor microRNA (let-7a) were shown to differentiate between high- and low-risk early breast cancer (EBC) and reflect the surgical tumor removal and adjuvant therapy. Here we applied the longitudinal multivariate data analyses to stochastically model the serum levels of each of the oncomiRs using the RT-PCR measurements in the EBC patients ( = 133) that were followed up 4 years after diagnosis. This study identifies that two of the studied oncomiRs, miR-155 and miR-24, are highly predictive of EBC relapse. Furthermore, combining the oncomiR level with Ki-67 expression further specifies the relapse probability. Our data move further the notion that oncomiRs in serum enable not only monitoring of EBC but also are a very useful tool for predicting relapse independently of any other currently analyzed characteristics in EBC patients. Our approach can be translated into medical practice to estimate individual relapse risk of EBC patients.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms18102116